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Purpose: To evaluate neuroretinal function and anatomical outcomes in patients with neovascular 
age-related macular degeneration (AMD) after three treatments with ranibizumab.
Design: Observational case reports.
Methods: We investigated visual function in three patients, one female (80 years) and two 
male (77 and 74 years) with neovascular AMD. Twenty healthy participants served as control 
group. We measured visual acuity (Bailey-Lovie charts), contrast sensitivity (Pelli-Robson) 
and neuroretinal function using the multifocal electroretinogram (mfERG). Central macular 
thickness was evaluated using optical coherence tomography (OCT). Main outcome measures 
were central and peripheral mfERG peak to trough (N1P1) response density amplitudes and 
peak (P1) implicit times. All tests were performed before the ﬁ  rst treatment (baseline) and after 
each of the three treatments with intravitreal 0.3 mg ranibizumab.
Results: Visual acuity and contrast sensitivity remained stable or improved. Central macular 
thickness decreased after three treatments in all three patients. We found no signiﬁ  cant change 
in central and peripheral neuroretinal function in the AMD patients between pre- and post-
treatments 2 and 3. Although the mfERG amplitudes in the AMD patients were not signiﬁ  cantly 
reduced compared with the age-similar group at baseline, there was a statistically signiﬁ  cant 
reduction in central and peripheral mfERG amplitudes after three treatments 
Conclusion: Anatomical outcomes and central visual function improved or remained stable 
in the three AMD patients in concordance with past reports. Further investigations of possible 
adverse effects of ranibizumab on the central and peripheral neuroretina in large prospective 
clinical trials are suggested.
Keywords: age-related macular degeneration, optical coherence tomography, OCT, multifocal 
electroretinogram, multifocal ERG, ranibizumab
Introduction
Targeting angiogenesis, the underlying mechanism promoting choroidal neovasculari-
sation is a new treatment alternative in neovascular age-related macular degeneration 
(AMD). Of the available antivascular endothelial growth factor (anti-VEGF) drugs 
(Gragoudas et al 2004; Avery et al 2006; VISION 2006), ranibizumab has been dem-
onstrated to stabilize/or improve visual acuity and anatomical outcomes in patients 
with neovascular (AMD), in large clinical trials (Brown et al 2006; Rosenfeld et al 
2006a, 2006d). Ranibizumab is a murine, monoclonal anti-VEGF antibody given 
intravitreally every four weeks. Its monthly application is based upon studies in pri-
mates that showed its rapid distribution in the retina (6–24 hours) and three day half 
life before its clearance from all ocular compartments (Gaudreault et al 2005). While 
its most favourable outcomes (prevention of visual acuity loss in 95% of patients and 
improvement in visual acuity in 25%–30% of patients) have been described when 
given monthly over a period of two years (Brown et al 2006; Rosenfeld et al 2006a), Clinical Ophthalmology 2007:1(2) 168
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new treatment strategies in combination with photodynamic 
therapy are being extensively investigated (Dhalla et al 2006; 
Heier et al 2006). Mild adverse effects after treatment with 
ranibizumab, such as conjunctival hyperaemia and subcon-
junctival haemorrhage have been reported in about 80% of 
patients and serious complications such as endophthalmitis 
and uveitis were evident in about 1%–1.3% (Rosenfeld et al 
2006c). Ongoing clinical trials are currently investigating 
the effect of less frequent dosing regimens. These studies 
indicate that optical coherence tomography (OCT) is help-
ful in retreatment decisions (Lalwani et al 2006; Rosenfeld 
et al 2006b).
While studies with anti-VEGF drugs have investigated 
its toxicity and penetration in animals (Manzano et al 2006; 
Shahar et al 2006), only two studies have measured local 
cellular function in humans. Both studies suggest further 
evaluation of neuroretinal function (Maturi et al 2006; 
Moschos et al 2007). Maturi and colleagues (2006) showed 
that there was no deterioration of neuroretinal function after 
one intravitreal treatment with bevacizumab, another anti-
VEGF drug which has been used ‘off-label’ for treatment of 
AMD (Rosenfeld 2006). They showed some small improve-
ment of central neuroretinal activity compared with baseline 
which they attributed to variability in the results rather than a 
recovery of function. The authors concluded that testing over 
a longer term was necessary (Maturi et al 2006). Moschos 
et al (2007) found no improvement in retinal function as 
measured using the mfERG after one bevacizumab injection 
after three months in 56% of their patients. While there was 
some improvement in amplitude on average compared with 
baseline, they attributed this to a decrease in macular edema 
rather than recovery of neuroretinal function. No published 
study has evaluated neuroretinal function after multiple treat-
ments with ranibizumab.
In the small series of neovascular AMD patients 
considered here, we extend the information about neuro-
retinal function after anti-VEGF therapy by monitoring 
patients who received several treatments with ranibizumab. 
The follow up of three treatments in this study is based on 
large clinical trials that currently test the drug efﬁ  cacy after 
an induction period of three monthly injections followed by 
quarterly injections (Rosenfeld et al 2006d). Besides well 
established visual acuity measures and OCT for monitoring 
treatment effects, we investigated contrast sensitivity and 
objectively documented central and peripheral neuroretinal 
function (up to 25 degree in diameter) with the multifocal 
electroretinogram (mfERG). A functional documentation of 
central and peripheral retinal areas is necessary to estimate 
a patient’s reading and mobility performance. So far, large 
clinical trials investigating anti-VEGF therapy have only 
reported visual acuity as a functional outcome measure. 
Visual acuity, however, reﬂ  ects function of only about the 
central 1 degree of the retina.
In addition to neuroretinal activity, the mfERG reﬂ  ects 
hypoxic effects on retinal function (Feigl et al 2007), which 
are likely to occur when there is choroidal atrophy. The 
latter has been described in relation to deprivation of  VEGF 
from the choroid as it may occur during anti-VEGF therapy 
(McLeod et al 2002; Marneros et al 2005).
Methods
Participants
We investigated three patients (1 female, 2 male) aged 80 y 
(AMD 1), 77 y (AMD 2) and 74 y (AMD 3), respectively. 
All patients had a diagnosis of neovascular AMD as assessed 
ophthalmoscopically and by fluorescein angiography. 
Patients were treated with 0.3 mg ranibizumab intravitreally 
by an ophthalmologist (AG) according to the recommended 
protocol (Rosenfeld et al 2006a). Participants were in good 
general health although one patient (AMD 3) had primary 
chronic open angle glaucoma which was well controlled 
by topical medication. Two of the participants (AMD 2 
and AMD 3) had a new choroidal neovascular membrane 
(CNV) and were treated with ﬁ  rst line therapy ranibizumab 
whereas patient 1 (AMD 1) had a recurrent CNV follow-
ing three preceding photodynamic therapies before she 
received ranibizumab. Twenty participants (aged between 
58 and 77 years, mean 69 ± 5) contributed to the healthy 
control group.
All patients gave written informed consent and the 
study was conducted in accordance with the tenets of 
the Declaration of Helsinki and the requirements of the 
Queensland University of Technology Human Research 
Ethics Committee.
Tests
All tests were performed under the instructions of the same 
researcher (BF). Visual acuity (VA) was assessed with Bailey 
Lovie charts (Bailey and Lovie 1976) at a starting distance 
of 6 m and contrast sensitivity with Pelli Robson charts at 
3 m (Pelli et al 1988). An improvement in visual acuity was 
deﬁ  ned as an increase of three lines (15 letters) (Rosenfeld 
et al 2006d) and improvement in contrast sensitivity as an 
increase of 6 letters (Rubin et al 2002). Macular thickness 
was measured using optical coherence tomography (OCT, 
Stratus III, Zeiss, Germany) (Hee et al 1995).Clinical Ophthalmology 2007:1(2) 169
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To evaluate neuroretinal activity we used the mfERG 
(VERIS, EDI, Redwood City, USA). The mfERG gives 
a topographical map of local neuroretinal function of the 
posterior pole. The waveform of the conventional fast ﬂ  icker 
application is thought to reﬂ  ect photoreceptor function and 
primarily ON and OFF bipolar cell function (Hood et al 
2002). In contrast to the full-ﬁ  eld ERG which gives a global 
retinal response, the mfERG allows the derivation of many 
local areas of the central and peripheral retina between 25 
to 50 degrees in diameter. The mfERG has been shown 
to be particularly useful in documenting treatment effects 
in the central and peripheral retina in AMD and diabetes 
(Greenstein et al 2000; Moschos et al 2001; Feigl et al 2005; 
Maturi et al 2006).
The visual stimulus of the mfERG consisted of 103-scaled 
black and white hexagons displayed on a calibrated 7-inch 
CRT monitor. Figure 1 demonstrates the stimulus array extend-
ing to 25 degrees in diameter (left), the local 103 waveform 
responses corresponding with each of the stimulated retinal 
areas (middle), and a three dimensional response density map 
of the retinal responses. The responses are higher centrally 
and decrease with increasing eccentricity according to the 
topographical distribution of cone photoreceptors and their 
associated postreceptoral pathways (Sutter and Tran 1992).
Participants were instructed to ﬁ  xate on a large central 
cross at the center of a CRT monitor and were corrected for 
the test distance using an eye monitor/refraction unit. Pupils 
were dilated using tropicamide 0.5% and phenylephrine 
2.5%. The black and white hexagons ﬂ  ickered according to 
a pseudorandom m-sequence where the CRT monitor screen 
was refreshed every 13.33 ms (75 Hz frame rate) (Zele and 
Vingrys 2005). The mfERG was recorded monocularly 
with DTL (Dawson-Trick-Litzkow) thread electrodes that 
were placed across the bulbar conjunctiva. The reference 
Ag-AgCl cup electrodes were placed on the temple close to 
the testing eye and the ground was placed on the forehead. 
Retinal signals were band pass ﬁ  ltered (10–300 Hz), sampled 
every 0.83 ms and ampliﬁ  ed (50,000x, Grass ampliﬁ  er). 
Recordings were made under ambient room light conditions. 
An eye camera and the on-line signal were used for monitor-
ing ﬁ  xation and blinks; small eye movements and artefacts 
detected during the recording caused signal segments to be 
rejected and re-recorded.
We analysed N1P1 peak to trough response densities 
(amplitudes per unit retinal area, in nV/deg2) and peak P1 
implicit times (time from the onset of the stimulus to the 
ﬁ  rst positive peak, in ms) as shown in Figure 2 (left). Before 
analysing the ﬁ  rst order kernel (mean local responses to all 
stimuli in a stimulus cycle) amplitudes and implicit times, 
one spatial averaging procedure (ratio = 6) and one noise 
reduction procedure were performed on the raw mfERG data 
(see Sutter and Tran [1992]).
Statistical analysis
Main outcome variables were means of N1P1 amplitudes 
and peak P1 implicit times. For better signal to noise ratio, 
N1P1 amplitude and P1 implicit time waveform responses 
were averaged into a central (∼13.5°) and peripheral area 
(∼13.5°–25°) in diameter (Figure 2, right).
For statistical analysis, central and peripheral N1P1 ampli-
tude response densities and P1 implicit time averages of each 
AMD patient were compared with responses of the healthy 
age-similar group before and after three treatments. The central 
and peripheral N1P1 amplitudes and P1 implicit times were also 
compared within each AMD patient’s pre- and second and third 
treatment. A repeated measures ANOVA (SPSS-14) was used 
to identify a signiﬁ  cant (main) effect between the treatments and 
retinal locations (central and peripheral) between each AMD 
05 0 m s
50 nV
0.0 0.5    1.0 1.5   2.0 2.5 3.0 nV/deg2
Figure 1 The mfERG uses black and white hexagons presented on a monitor (left) that ﬂ  icker according to a pseudorandom m-sequence. Each waveform represents the 
electrical response from a hexagon which stimulates a focal retinal area.   The waveforms can be plotted as a trace array (middle) or as a three dimensional response density 
(amplitudes per unit retinal area) plot (right).   The latter reﬂ  ects the distribution of the cone-mediated (photoreceptor and bipolar) cellular responses.Clinical Ophthalmology 2007:1(2) 170
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patient and the healthy control group before and after three 
treatments and within each AMD patient’s treatments.
Results
Visual acuity, contrast sensitivity, optical coherence 
tomography (OCT), and the mfERG were performed before 
(a week or less) and three to four weeks after each of the 
three treatments. One patient (AMD 3) was not able to 
perform a mfERG after the ﬁ  rst treatment because of illness 
unrelated to the treatment. For uniform presentation of 
mfERG data, the results are reported before treatment, and 
after the second and third treatment in all participants.
Visual acuity improved by 6 lines and contrast sensitivity 
by 10 letters in one patient (AMD 3) and remained stable 
in AMD 1 and AMD 2 after three treatments with ranibi-
zumab (Table 1). Decreased central macular thickness was 
evident in all patients after three treatments compared with 
pre-treatment values. Patient AMD 1 still showed cystoid 
intraretinal ﬂ  uid formation after three treatments.
Comparison between AMD patients and 
healthy control group before and after 
three treatments
Before treatment (baseline) there was no statistically 
significant difference between central and peripheral 
N1P1 amplitudes of the healthy group and AMD patients 
(AMD 1: F1,18 = 2.0, p = 0.2, AMD 2: F1,18 = 3.4, p = 0.1, 
AMD 3, F1,18 = 0.002, p = 0.9). After the third treatment central 
and peripheral N1P1 amplitudes signiﬁ  cantly decreased in 
AMD 1 (F1,18 = 4.3, p  0.05), AMD 2 (F1,18 = 3.9, p  0.05) 
and AMD 3 (F1,18 F = 6.0, p = 0.03) when compared with 
the healthy control group (Figure 3, upper panel). Central 
and peripheral P1 implicit times were signiﬁ  cantly delayed 
before treatment in AMD 1 (F1,18 = 33.1, p  0.001) and 
AMD 3 (F1,18 = 43.4, p  0.001) and were not signiﬁ  cantly 
different in AMD 2 (F1,18 = 1.8, p = 0.2) compared with the 
healthy group, and this did not change after three treatments 
(Figure 3, lower panel).
Comparison within pre-treatment and 
post-treatment values in AMD patients
Table 2 demonstrates the central and peripheral N1P1 
response densities and P1 implicit times before and after 
Figure 2 The stimulus array (right) and how the waveform responses were averaged into a central (1) and peripheral (2) area are shown.   We analyzed N1P1 trough to peak 
amplitude response densities and P1 peak implicit times (arrows).
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Table 1 The patient’s visual acuity (VA), contrast sensitivity 
(Contrast) and OCT
VA Contrast 
(letters)
OCT
(microns-central
1 mm)
AMD 1 (left eye)
Before 6/30 21 319
After 2 6/30 21 200
After 3 6/48 24 223
AMD 2 (left eye)
Before 6/9.5 34 388
After 2 6/9.5 34 194
After 3 6/9.5 34 201
AMD 3 (right eye)
Before 6/30 23 279
After 2 6/15 26 237
After 3 6/7.5 33 245Clinical Ophthalmology 2007:1(2) 171
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treatments 2 and 3 for each AMD patient. There was no 
statistically signiﬁ  cant change in central and peripheral 
N1P1 amplitudes for AMD 1 (F1,2 = 17, p = 0.2), AMD 
2 (F1,2 = 55.6, p = 0.1) and AMD 3 (F1,2 = 112, p = 0.1) 
before and after treatments 2 and 3 when compared with 
pre-treatment. Also, central and peripheral P1 implicit 
times were not signiﬁ  cantly different to pre-treatment 
values in all patients (AMD 1: F1,2 = 8.2, p = 0.2, AMD 2: 
F1,2 = 2.5, p = 0.4 and AMD 3: F1,2 = 11.7, p = 0.2) after 
treatments 2 and 3.
Figures 4 shows the mfERG averaged central and periph-
eral ring responses (a) and OCT (b) before and after three 
treatments with ranibizumab from AMD patient 1, AMD 
patient 2, and AMD patient 3. The three dimensional ampli-
tude response density plots (c) for each patient demonstrate 
lower responses (as indicated in darker gray scale areas) 
after three treatments compared with the healthy control 
group.
Discussion
After three treatments with ranibizumab, all AMD patients 
had stable or improved visual acuity and contrast sensitivity 
and a decrease in central macular thickness compared with 
pretreatment values (Table 1). While neuroretinal function 
remained stable within the treatments (Table 2), there was a 
signiﬁ  cant decrease in central and peripheral mfERG ampli-
tudes for all patients compared with a healthy age-similar 
group after three treatments (Figure 3). Our ﬁ  ndings of no 
signiﬁ  cant change compared with baseline values are in con-
cordance with other studies investigating neuroretinal func-
tion after one treatment with anti-VEGF (Maturi et al 2006; 
Moschos et al 2007). However, these studies did not include a 
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Figure 3 The N1P1 amplitudes ± SD (A) and peak implicit times ± SD (B) for the central and peripheral rings for each ARM patient are shown compared with a healthy 
control group.   While P1 implicit times remained stable, N1P1 amplitudes were signiﬁ  cantly reduced after the third treatment.Clinical Ophthalmology 2007:1(2) 172
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Figure 4 The mfERG and OCT results for the AMD 1 (A),   AMD 2 (B) and AMD 3 (C) are demonstrated.   The mfERG central and peripheral area waveform averages (a) 
and OCT images (b) before and after three treatments are shown for each patient. In c. the three dimensional response density plots of each patient compared with the age-
similar control group (n = 20) are outlined before and after three treatments with ranibizumab. Note that darker gray scales indicate poorer response densities which were 
evident in all patients after the third treatment.   These were not only reduced in the central area but throughout the whole ﬁ  eld up to 25° (see also waveform averages in a).Clinical Ophthalmology 2007:1(2) 173
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control group. We extend this observation to show that AMD 
patients have a signiﬁ  cant reduction in amplitudes compared 
with an age-similar control group after three treatments.
The mfERG can measure function in localized retinal 
areas and in our study, areas of approximately 13.5° (central) 
and 13.5°–25° (peripheral) in diameter. In contrast visual acu-
ity only reﬂ  ects the function of the foveal area which is less 
than one degree of visual angle. The mfERG therefore better 
represents areas covered by the neovascularisation membrane 
than visual acuity. In addition although anti-VEGF targets 
new vessel growth, it is not clear if there are adverse effects 
on the healthy peripheral retina. Our ﬁ  ndings of impaired 
central and peripheral neuroretinal function compared with 
a healthy control group after three treatments, suggest a more 
widespread effect of the anti-VEFG therapy on the retina than 
the clinically deﬁ  ned area affected by AMD.
In concordance with other studies we found stable or 
improved visual acuity. Anti-VEGF drugs reduce vascular 
permeability (Witmer et al 2003) and a reduction in macular 
edema alone, could have resulted in recovery or stabilization 
of foveal visual acuity (Costa et al 2006). However, a reduced 
edema might not recover neuroretinal function. Recently 
Moschos and colleagues (2007) reported a discrepancy 
between functional (visual acuity and electrophysiology) 
and anatomical outcomes (OCT) of patients after one bevaci-
zumab treatment. Functional outcomes did not improve with 
the decrease in macular thickness after three months. They 
suggested that “macular edema is only a parameter that may 
affect visual acuity and electrophysiological responses in the 
beginning of the disease” (Moschos et al 2007). This implies 
disruption of delicate intraretinal mechanisms subserving 
psychophysical and electrophysiological responses that do 
not resolve after resolution of the edema.
We are aware that patients were still undergoing 
treatment that was not yet complete and the recovery 
of neuroretinal function might occur over a longer time 
course. In particular amplitude recovery might take more 
than three treatments given that a decrease in amplitude 
reﬂ  ects widespread cellular alteration (Gerth et al 2003). 
However, adverse effects of anti-VEGF interfering 
with central and peripheral neuroretinal activity may 
have been evident in our mfERG results. While a lack 
of   improvement of central neuroretinal function could 
have indicated the natural course of progression in AMD 
(Jurklies et al 2002), a central and peripheral functional 
deﬁ  cit, as detected in this study, may suggest a broader, 
possibly adverse effect. It is well established that VEGF 
is essential for choriocapillaris development (Marneros 
et al 2005). In addition VEGF has a neuroprotective role 
(Robinson et al 2001; Storkebaum et al 2004) and essential 
role in physiological angiogenesis such as the regulation 
of embryonic and postnatal processes (Gerber et al 1999), 
the regulation of vascular and nervous networks in the 
heart and brain (Galvan et al 2006; Maulik 2006), wound 
healing (Schlingemann 2004) and the regulation of anti-
thrombotic processes (Manley et al 2002). Inhibition or 
manipulation of VEGF could be harmful in the develop-
ing retina, but also in hypoxic retinal tissue (Robinson 
et al 2001). Hypoxia and ischemia have been discussed in 
AMD (Pauleikhoff et al 1990; Grunwald et al 1998, 2005; 
Arden et al 2005; Feigl et al 2006) and while a normal 
retina might tolerate successive treatment with anti-VEGF, 
a hypoxic “pre-injured” retina might not.
This is the ﬁ  rst report of the effect of multiple treatments 
with ranibizumab on neuroretinal function. Although we have 
described this effect in only a small number of patients, we 
Table 2 The central and peripheral N1P1 response density (above) and P1 implicit time
N1P1 in nV/deg2 Before After 2 After 3
Area central peripheral central peripheral central peripheral
AMD 1 3.7 3.1 2.8 2.1 3.2 2.1
AMD 2 3.7 2.2 5.2 2.6 3.7 1.8
AMD 3 5.6 4.3 3.1 2.0 2.9 1.6
Note: (below) values before and after treatment 2 and 3 for each AMD patient.
P1 in ms Before After 2 After 3
Area central peripheral central peripheral central peripheral
AMD 1 36.6 35.4 37.5 37.5 35.0 35.4
AMD 2 31.3 29.2 31.3 29.6 31.7 30.4
AMD 3 37.1 37.1 31.7 31.7 35.5 36.7Clinical Ophthalmology 2007:1(2) 174
Feigl et al
want to raise awareness of possible adverse effects on the 
central and peripheral neuroretina. Our results should encour-
age large controlled trials to include vision measures other 
than visual acuity and OCT in documenting treatment effects 
of anti-VEGF therapy. Ideally these should give measures 
of central and peripheral neuroretinal function, as well as 
measures reﬂ  ecting choroidal perfusion.
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